CNS PharmaceuticalsCNS PharmaceuticalsCNS Pharmaceuticals
  • Brain
    • Glioblastoma
    • Anthracyclines
    • Blood Brain Barrier
  • Technology
    • Berubicin
    • Pipeline
  • Team
    • Management
    • Board
  • About Us
  • Contact
  • Investors
  • Sign Up

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Analyst Coverage
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

CNS Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020

May 27, 2020 6:00pm EDT

CNS Provides Update on Development Agreement for WP1122

May 27, 2020 4:10pm EDT

CNS Announces Nasdaq Trading Halt Pending Receipt of Additional Information

May 18, 2020 8:00am EDT

CNS Provides Additional Comments Regarding Trading Halt

May 11, 2020 8:00am EDT

CNS Pharmaceuticals Announces Trading Halt

May 04, 2020 7:12pm EDT

CNS Pharmaceuticals and WPD Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial

Apr 30, 2020 8:00am EDT

CNS Pharmaceuticals Announces Filing of FDA Orphan Drug Designation for Brain Cancer Drug Berubicin

Apr 23, 2020 8:00am EDT

CNS Pharmaceuticals to Host Shareholder Webinar Today to Discuss Coronavirus Collaboration, the Significance of WP1244, and an Update on the Cancer Free Survivor Treated with Berubicin

Apr 22, 2020 8:00am EDT

CNS Pharmaceuticals Announces Shareholder Webinar to Discuss Collaboration with WPD Pharmaceuticals for Developing Coronavirus Drug Candidates, the Significance of WP1244, and an Update on the Cancer Free Survivor Treated with Berubicin

Apr 15, 2020 8:00am EDT

CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with WPD Pharmaceuticals

Apr 13, 2020 8:00am EDT
RSS
  • Prev
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    © 2023 CNS Pharmaceuticals. All Rights Reserved, CNS Pharma

    • Brain
      • Glioblastoma
      • Anthracyclines
      • Blood Brain Barrier
    • Technology
      • Berubicin
      • Pipeline
    • Team
      • Management
      • Board
    • About Us
    • Contact
    • Investors
    • Sign Up